Endothelial Dysfunction and Diabetic Cardiomyopathy
- PMID: 35464057
- PMCID: PMC9021409
- DOI: 10.3389/fendo.2022.851941
Endothelial Dysfunction and Diabetic Cardiomyopathy
Abstract
The cardiovascular complications contribute to a majority of diabetes associated morbidity and mortality, accounting for 44% of death in those patients with type 1 diabetes mellitus (DM) and 52% of deaths in type 2 DM. Diabetes elicits cardiovascular dysfunction through 2 major mechanisms: ischemic and non-ischemic. Non-ischemic injury is usually under-recognized although common in DM patients, and also a pathogenic factor of heart failure in those diabetic individuals complicated with ischemic heart disease. Diabetic cardiomyopathy (DCM) is defined as a heart disease in which the myocardium is structurally and functionally abnormal in the absence of coronary artery disease, hypertensive, valvular, or congenital heart disorders in diabetic patients, theoretically caused by non-ischemic injury solely. Current therapeutic strategies targeting DCM mainly address the increased blood glucose levels, however, the effects on heart function are disappointed. Accumulating data indicate endothelial dysfunction plays a critical role in the initiation and development of DCM. Hyperglycemia, hyperinsulinemia, and insulin resistance cause the damages of endothelial function, including barrier dysfunction, impaired nitric oxide (NO) activity, excessive reactive oxygen species (ROS) production, oxidative stress, and inflammatory dysregulation. In turn, endothelial dysfunction promotes impaired myocardial metabolism, intracellular Ca2+ mishandling, endoplasmic reticulum (ER) stress, mitochondrial defect, accumulation of advanced glycation end products, and extracellular matrix (ECM) deposit, leads to cardiac stiffness, fibrosis, and remodeling, eventually results in cardiac diastolic dysfunction, systolic dysfunction, and heart failure. While endothelial dysfunction is closely related to cardiac dysfunction and heart failure seen in DCM, clinical strategies for restoring endothelial function are still missing. This review summarizes the timely findings related to the effects of endothelial dysfunction on the disorder of myocardium as well as cardiac function, provides mechanical insights in pathogenesis and pathophysiology of DCM developing, and highlights potential therapeutic targets.
Keywords: diabetes; diabetic cardiomyopathy; endothelial dysfunction; metabolism; oxidative stress.
Copyright © 2022 Wang, Li, Li and Lv.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy.Int J Mol Sci. 2019 Jul 2;20(13):3264. doi: 10.3390/ijms20133264. Int J Mol Sci. 2019. PMID: 31269778 Free PMC article. Review.
-
The Role of Cardiac Fibrosis in Diabetic Cardiomyopathy: From Pathophysiology to Clinical Diagnostic Tools.Int J Mol Sci. 2023 May 11;24(10):8604. doi: 10.3390/ijms24108604. Int J Mol Sci. 2023. PMID: 37239956 Free PMC article. Review.
-
Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.Circ Res. 2018 Feb 16;122(4):624-638. doi: 10.1161/CIRCRESAHA.117.311586. Circ Res. 2018. PMID: 29449364 Free PMC article. Review.
-
Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants.Heart Fail Rev. 2023 May;28(3):597-606. doi: 10.1007/s10741-021-10200-y. Epub 2022 Jan 10. Heart Fail Rev. 2023. PMID: 35001338 Review.
-
Diabetic Cardiomyopathy: From Mechanism to Management in a Nutshell.Endocr Metab Immune Disord Drug Targets. 2021;21(2):268-281. doi: 10.2174/1871530320666200731174724. Endocr Metab Immune Disord Drug Targets. 2021. PMID: 32735531 Review.
Cited by
-
Nomogram based on multimodal echocardiography for assessing the evolution of diabetic cardiomyopathy in diabetic patients with normal cardiac function.Front Cardiovasc Med. 2022 Sep 20;9:1002509. doi: 10.3389/fcvm.2022.1002509. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36204578 Free PMC article.
-
Myocardial protection of S-nitroso-L-cysteine in diabetic cardiomyopathy mice.Front Endocrinol (Lausanne). 2022 Oct 12;13:1011383. doi: 10.3389/fendo.2022.1011383. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36313766 Free PMC article.
-
Tongxinluo Activates PI3K/AKT Signaling Pathway to Inhibit Endothelial Mesenchymal Transition and Attenuate Myocardial Fibrosis after Ischemia-Reperfusion in Mice.Chin J Integr Med. 2024 Jul;30(7):608-615. doi: 10.1007/s11655-024-3652-5. Epub 2024 Feb 22. Chin J Integr Med. 2024. PMID: 38386252
-
Optimisation of an in vitro human cardiovascular model on-a-chip for toxicological assessment of nicotine delivery products.Front Toxicol. 2024 Jun 13;6:1395670. doi: 10.3389/ftox.2024.1395670. eCollection 2024. Front Toxicol. 2024. PMID: 38938662 Free PMC article.
-
Cardiorenal syndrome and diabetes: an evil pairing.Front Cardiovasc Med. 2023 May 10;10:1185707. doi: 10.3389/fcvm.2023.1185707. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37234376 Free PMC article. Review.
References
-
- Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. . Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results From the International Diabetes Federation Diabetes Atlas, 9 Edition. Diabetes Res Clin Pract (2019) 157:107843. doi: 10.1016/j.diabres.2019.107843 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous